NPS Program

NPS Program

TOPNPS Program

JCR Pharmaceuticals implements IZCARGO® for I.V. infusion 10mg Named Patient Supply Program

JCR Pharmaceuticals Co., Ltd. (“JCR”) has implemented a Named Patient Supply Program for IZCARGO® for I.V. infusion 10mg (“IZCARGO®” JAN: Pabinafusp Alfa (Genetical Recombination)) for patients with Mucopolysaccharidosis type II (MPS II or Hunter syndrome).

The Named Patient Supply Program will enable early access to IZCARGO® for eligible patients in certain countries where it is not commercially available yet. IZCARGO® is currently only approved in Japan. JCR has signed an agreement with Clinigen to implement the Named Patient Supply Program. Under the terms of the agreement, Clinigen will manage key elements of the program including regulatory oversight, logistics and access management.

Healthcare professionals can obtain details about the IZCARGO® Named Patient Supply Program by calling the customer service team at +44 (0) 1932 824 100 or emailing
Patients seeking medical information should contact their physician.